Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Gano

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Practice|January 1, 1995
Administration of liposomal MTP-PE by the local physician: the role of the research nurseJ B Gano, E S Kleinerman
Oncology Nursing Forum|June 1, 1995
Liposomal MTP-PE: a promising new biologic response modifierJ B Gano, E S Kleinerman
American Journal of Clinical Oncology|April 1, 1995
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcomaE S Kleinerman, J B Gano, D A Johnston, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1995
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulationE S Kleinerman, P A Meyers, A K Raymond, et al.
Cancer Biotherapy|January 1, 1993
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid)W Fujimaki, K Itoh, T An, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Practice|January 1, 1995
Administration of liposomal MTP-PE by the local physician: the role of the research nurseJ B Gano, E S Kleinerman
Oncology Nursing Forum|June 1, 1995
Liposomal MTP-PE: a promising new biologic response modifierJ B Gano, E S Kleinerman
American Journal of Clinical Oncology|April 1, 1995
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcomaE S Kleinerman, J B Gano, D A Johnston, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1995
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulationE S Kleinerman, P A Meyers, A K Raymond, et al.
Cancer Biotherapy|January 1, 1993
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid)W Fujimaki, K Itoh, T An, et al.
Pageof 1